既往联合使用他汀与ACE-I/ARB的患者颈动脉血运重建后结局优于单用他汀者:多中心分析
基于血管质量倡议(VQI)2016至2021年数据,纳入131285例颈动脉血运重建患者,比较术前单用他汀(59860例)与联用他汀和ACE-I/ARB(71425例)的结局。校正混杂因素后,联合组术后死亡/卒中风险降低12%(IRR 0.88,95%CI 0.81-0.95,P=0.001),术后充血性心力衰竭风险降低18%(IRR 0.82,95%CI 0.68-0.98,P=0.029),术后心肌梗死风险相似(IRR 1.05,95%CI 0.91-1.20,P=0.54)。作者推荐颈动脉血运重建患者继续使用ACE-I/ARB,尤其合并高血压者。
要点
- 联合组较单用他汀组术后死亡/卒中风险降低12%(IRR 0.88,95%CI 0.81-0.95,P=0.001)。
- 联合组较单用他汀组术后充血性心力衰竭风险降低18%(IRR 0.82,95%CI 0.68-0.98,P=0.029)。
- 两组术后心肌梗死风险相似(IRR 1.05,95%CI 0.91-1.20,P=0.54)。
核心结论
- 颈动脉血运重建围术期他汀联合ACE-I/ARB较单用他汀提供更好的保护。
- 作者推荐颈动脉血运重建患者继续使用ACE-I/ARB,尤其合并高血压者。
- 作者认为需要进一步前瞻性研究评估加用ACE-I/ARB的获益。
研究设计与样本
- 多中心分析,使用血管质量倡议(VQI)2016至2021年数据。
- 纳入接受颈动脉血运重建(包括CEA、经颈动脉血运重建和经股动脉颈动脉支架置入)的全部患者131285例。
- 单用他汀组59860例(46%),他汀联合ACE-I/ARB组71425例(54%)。
- 采用泊松回归(稳健方差)比较联合组与单用他汀组的术后结局。
主要发现
- 联合组较单用他汀组术后死亡/卒中风险降低12%(IRR 0.88,95%CI 0.81-0.95,P=0.001)。
- 联合组较单用他汀组术后充血性心力衰竭风险降低18%(IRR 0.82,95%CI 0.68-0.98,P=0.029)。
- 联合组与单用他汀组术后心肌梗死风险相似(IRR 1.05,95%CI 0.91-1.20,P=0.54)。
- 两组术前临床和人口学特征差异显著。
临床怎么用
- 作者推荐颈动脉血运重建患者继续使用ACE-I/ARB,尤其合并高血压者。
- 作者认为需要进一步前瞻性研究评估加用ACE-I/ARB的获益。
局限性
- 作者认为需要进一步前瞻性研究评估加用ACE-I/ARB的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Statin use has been studied and confirmed to have a beneficial impact on perioperative carotid endarterectomy (CEA) and carotid artery stenting (CAS) outcomes. The benefits of Angiotensin-converting enzyme inhibitors (ACE-I) in hypertension, ischemic heart disease, heart failure, diabetes mellitus, and renal disease are well-known; however, the impact of continuing or withholding ACE-Is/angiotensin receptor blockers (ARBs) on CEA and CAS outcomes is not addressed well in the literature. This study aimed to evaluate the impact of preoperative statin use combined with ACE-Is/ARBs in patients undergoing CEA or CAS on mortality and morbidity using a multi-institutional database. METHODS: Using the data of all patients who underwent carotid artery revascularization, including CEA, transcarotid artery revascularization, and transfemoral carotid artery stenting from 2016 to 2021 in the Vascular Quality Initiative data, we determined as our primary outcome 30-day mortality/stroke after carotid revascularization based on periop exposure to statins alone, or the combination of statins and ACE-Is/ARBs. Secondary outcomes were postop myocardial infarction and postop congestive heart failure. Poisson regression with robust variance was used to determine postop outcomes comparing the combination of statin and ACE-Is/ARBs group with statins alone group. RESULTS: A total of 131,285 patients were included in the study, with 59,860 (46%) patients receiving statin only, and 71,425 (54%) receiving both statin and ACE-Is/ARBs preoperatively. Both patient groups differed significantly in preop clinical and demographic characteristics. After adjusting for potential confounders, the statins plus ACE-I/ARB group had a 12% lower risk of postop mortality/stroke (Incident Rate Ratio comparing Statin/ACE group to Statins Only group [IRR] 0.88, 95% confidence interval 0.81-0.95, P = 0.001), 18% lower risk of postop congestive heart failure (IRR 0.82, 95% CI 0.68-0.98, P = 0.029), and similar risk of postop myocardial infarction (IRR 1.05 95% confidence interval 0.91-1.20, P = 0.54) compared to the statin-only group. CONCLUSION: Statins combined with ACE-Is/ARBs perioperatively offer better protection compared to statins alone in patients undergoing carotid revascularization surgery. We recommend the continuation of ACE-Is/ARBs use in patients undergoing carotid revascularization, especially if they have concurrent hypertension. Further prospective studies are needed to evaluate the benefit of adding ACE-Is/ARBs.
引用
- Willie-Permor D, Rahgozar S, Zarrintan S, et al. Patients with Prior Exposure to a Combination of Statins & Angiotensin-Converting Enzyme Inhibitors (ACE-Is)/Angiotensin Receptor Blockers (ARBs) Have Better Outcomes after Carotid Revascularization than Patients with Prior Exposure to Statins Alone: A MultiCenter Analysis. Ann Vasc Surg. 2023. PMID: 37852362. doi:10.1016/j.avsg.2023.08.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。